account_id none on file
legal_name ProQR Therapeutics N.V.
ticker PRQR
cik 1612940
domain proqr.com
linkedin_company_url https://www.linkedin.com/company/proqr-therapeutics-bv/
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 15 executives 9 family 0
why_nownone on file
callsnone on file
filings
Dennis Hom has served as our Chief Financial Officer since May 2025 and oversees all finance and corporate development functions, including investor relations, and business development.
filing / Mar 12, 2026 / receipt
In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures.
filing / Mar 12, 2026 / receipt
The Medicare Modernization Act, including its cost reduction initiatives, could decrease the coverage and reimbursement rate that we or a collaborator receive for any of our approved products.
filing / Mar 12, 2026 / receipt
As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs, would make some activities more time consuming and costly and could necessitate the hiring of additional accounting, financial and legal staff.
filing / Mar 12, 2026 / receipt
The Company also leases a shared office space in the United States, at CIC Cambridge, located at 245 Main Street, Cambridge, MA 02142.
filing / Mar 12, 2026 / receipt
For more information as to the risks associated with our workforce reduction, see Item 3.D: “Risk Factors”. E. Share Ownership Refer to Item 7.A: “Major Shareholders” in this Annual Report.
filing / Mar 12, 2026 / receipt
Sheila Sponselee | | May 22, 1984 | | Chief People & Operations Officer
filing / Mar 12, 2026 / receipt
James Shannon. M.D. | | June 5, 1956 | | Non-executive director (Chairman) | | June 21, 2016 and chairman since May 22, 2024 | | 2029
filing / Mar 12, 2026 / receipt
Alison F. Lawton | | September 26, 1961 | | Non-executive director | | September 17, 2014 | | 2026
filing / Mar 12, 2026 / receipt
Bart Filius | | July 5, 1970 | | Non-executive director | | May 21, 2019 | | 2027
filing / Mar 12, 2026 / receipt
Theresa Heggie | | November 17, 1960 | | Non-executive director | | May 18, 2023 | | 2027
filing / Mar 12, 2026 / receipt
Daniel de Boer | April 12, 1983 | | Chief Executive Officer and Executive director | | February 21, 2012 | | 2029
filing / Mar 12, 2026 / receipt
executives
| Alison F. Lawton | Non-executive director | - | receipt |
| Bart Filius | Non-executive director | - | receipt |
| Cristina Lopez | Chief Medical Officer | - | receipt |
| Daniel de Boer | Chief Executive Officer and Executive director | - | receipt |
| Dennis Hom | CFO | receipt | |
| Gerard Platenburg | Chief Scientific Officer and Executive director | - | receipt |
| James Shannon. M.D. | Non-executive director (Chairman) | - | receipt |
| Sheila Sponselee | Chief People & Operations Officer | - | receipt |
| Theresa Heggie | Non-executive director | - | receipt |
familynone on file
upcoming
changesnone on file
mcp_package_hint
slug proqr-therapeutics-n-v
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$